IQVIA艾昆纬：2025年生物制药创新领域重拾发展动力报告（英文版）

Biopharma funding levels in the past year continued to increase following the post-pandemic rebound of 2023, with growth contributions coming from IPOs, follow-on funding, and other public and private sources. Excluding the 2020 and 2021 heights seen during the pandemic, funding reached a 10 year high of $102Bn in 2024 — a substantial increase on the 2023 figure of $71Bn. In contrast, the volume of R&D deals between pharmaceutical companies declined in 2024, continuing the downwar